FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast CancerLaleh Amiri‐Kordestani, Patricia Cortazar, Shenghui Tang et al.|Clinical Cancer Research|2014Cited by 350
Exposure–Response Relationship of T-DM1: Insight Into Dose Optimization for Patients With HER2-Positive Metastatic Breast CancerJ Wang, Atiqur Rahman, Pengfei Song et al.|Clinical Pharmacology & Therapeutics|2014Cited by 65